Does Induction with Misoprostol Impact the Small for Gestational Age Neonate?

Area of Science:

• Obstetrics and Gynecology
• Neonatal Medicine
• Perinatal Research

Background:

• Cervical ripening agents are crucial for labor induction.
• Assessing the safety of misoprostol in small for gestational age (SGA) neonates is important.
• Previous studies have not definitively compared misoprostol with other agents in this specific population.

Purpose of the Study:

• To compare adverse outcomes in SGA neonates induced with misoprostol versus other cervical ripening agents.
• To determine if misoprostol increases the risk of negative neonatal outcomes.
• To evaluate the efficacy and safety of misoprostol for labor induction in SGA pregnancies.

Main Methods:

• Retrospective analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Consortium on Safe Labor database.
• Comparison of SGA neonates (<10th percentile) induced with misoprostol ± oxytocin (n=451) versus prostaglandin E2 ± oxytocin and/or mechanical dilation ± oxytocin (n=663).
• Primary outcomes included intrapartum fetal distress, cesarean section rates, NICU admission, low 5-minute Apgar, and composite neonatal morbidity, analyzed using logistic regression.

Main Results:

• Misoprostol induction in SGA neonates was associated with significantly decreased low 5-minute Apgar scores (aOR 0.27 [0.10-0.71]).
• No significant differences in adverse outcomes were observed for very small for gestational age neonates (<5th percentile).
• No increased risk of intrapartum fetal distress, cesarean section, or neonatal intensive care unit admission was found.

Conclusions:

• Misoprostol appears to be a safe cervical ripening agent for SGA neonates, not increasing adverse outcomes.
• The study suggests misoprostol may be a favorable option for labor induction in SGA pregnancies.
• Further prospective research is recommended to confirm these findings and establish optimal induction protocols for SGA neonates.